Algorithm for the treatment of major depression in patients with advanced cancer

Psychiatry and Clinical Neurosciences

Volumn 53, Issue SUPPL., 1999, Pages

  Nakano, Tomohito ^b   Kugaya, Akira ^b   Akechi, Tatsuo ^b   Mikami, Ichiro ^b   Okuyama, Toru ^b   Okamura, Hitoshi ^b   Uchitomi, Yosuke ^a  

^a NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^b NONE

Author keywords

Algorithm; Antidepressant; Cancer; Major depression

Indexed keywords

ALPRAZOLAM; ANTIDEPRESSANT AGENT; BENZODIAZEPINE DERIVATIVE; METHYLPHENIDATE; SULPIRIDE;

ADVANCED CANCER; ALGORITHM; CANCER PATIENT; CLINICAL PRACTICE; CONFERENCE PAPER; DEPRESSION; HUMAN; PSYCHOPHARMACOLOGY;

ALGORITHMS; ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER, MAJOR; HUMANS; NEOPLASMS; PATIENT CARE TEAM; SICK ROLE; TRUTH DISCLOSURE;

EID: 0032730317     PISSN: 13231316     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (33)

1. Derogatis LR, Morrow GR, Fetting J et al. The prevalence of psychiatric disorders among cancer patients. JAMA 1983;249:751-757.
2. Minagawa H, Uchitomi Y, Yamawaki S et al. Psychiatric morbidity in terminally ill cancer patients. A prospective study. Cancer 1996; 78: 1131-1137.
3. Okamura H, Akechi T, Uchitomi Y et al. Depression in patients with advanced cancer. In: Eguchi K, Klastersky J, Feld R (eds) Current Perspectives and Future Directions in Palliative Medicine. Springer-Verlag, Tokyo, 1998; 67-76.
4. Hosaka T, Aoki T. Depression among cancer patients. Psychiatry Clin. Neurosci. 1996; 50:309-312.
5. Chochinov HM, Wilson KG, Enns M et al. Desire for death in the terminally ill. Am. J. Psychiatry 1995; 152: 1185-1191.
6. Groenwoud JH, van der Maas PJ, van der Wal G et al. Physician-assisted death in psychiatric practice in the Netherlands. N. Engl. J. Med. 1997; 336: 1795-1801.
7. Massie MJ, Holland JC. Depression and the cancer patient. J. Clin. Psychiatry 1990; 51: 12-17.
8. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th edn. American Psychiatric Association, Washington DC, 1994.
9. Cassem EH. Depression and anxiety secondary to medical illness. Psychiatr. Clin. North Am. 1990; 13: 597-612.
10. Cohen-Cole SA, Brown F, McDaniel JS. Assessment of depression and grief reactions in the medically ill. In: Stroudemire A, Fogel BS (eds) Psychiatric Care of the Medical Patient. Oxford University Press, New York, 1993; 53-69.
11. McDaniel JS, Nemeroff CB. Psychological distress and depression. In: Abeloff MD, Armitage JO, Lichter AS et al. (eds) Clinical Oncology. Churchill Livingstone, New York, 1995; 373-391.
12. Breitbart W. Psycho-Oncology: Depression, anxiety, delirium. Semin. Oncol. 1994; 21: 754-769.
13. Kugaya A, Uchitomi Y. Medication. In: Yamawaki S, Uchitomi Y (eds) Psycho-oncology. Shinryoushinsya, Osaka, 1997; 188-196 (in Japanese).
14. Bruera E, Chadwick S, Brenneis C et al. Methyl-phenidate associated with narcotics for the treatment of cancer pain. Cancer Treat. Rep. 1987; 71: 67-70.
15. Lesko LM, Massie MJ, Holland JC. Oncology. In: Stroudemire A, Fogel BS (eds) Psychiatric Care of the Medical Patient. Oxford University Press, New York, 1993; 565-590.
16. Massie MJ, Lesko LM. Psychopharmacological management. In: Holland JC, Rowland JH (eds) Handbook of Psychooncology. Oxford University Press, New York, 1990; 470-491.
17. Olin J, Masand P. Psychostimulants for depression in hospitalized cancer patients. Psychosomatics 1996; 37: 57-62.
18. Passik SD, Breitbart WS. Depression in patients with pancreatic carcinoma. Diagnostic and treatment issues. Cancer 1996; 78: 615-626.
19. Wallace AE, Kofoed LL, West AN. Double-blind, placebo-controlled trial of methylphenidate in older, depressed, medically ill patients. Am. J. Psychiatry 1995; 152:929-931.
20. Cavanaugh S, Clark DC, Gibbons RD. Diagnosing depression in the hospitalized medically ill. Psychosomatics 1983; 24: 809-815.
21. Endicott J. Measurement of depression in patients with cancer. Cancer 1984; 53: 2243-2248.
22. Bukberg J, Penman D, Holland JC. Depression in hospitalized cancer patients. Psychosom. Med. 1984; 46: 199-221.
23. Breitbart W, Mermelstein H. Pemoline. An alternative psychostimulant for the management of depressive disorders in cancer patients. Psychosomatics 1992; 33: 352-356.
24. Holland JC, Morrow GR, Schmale A et al. A randomized clinical trial of alprazolam versus progressive muscle relaxation in cancer patients with anxiety and depressive symptoms. J. Clin. Oncol. 1991; 9: 1004-1011.
25. Overall JE, Biggs J, Jacobs M et al. Comparison of alprazolam and imipramine for treatment of outpatients depression. J. Clin. Psychiatry 1987; 48: 15-19.
26. Rush AJ, Erman MK, Schlesser MA et al. Alprazolam versus amitriptyline in depressions with reduced REM latencies. Arch. Gen. Psychiatry 1985; 42: 1154-1159.
27. U.S. Department of Health and Human Services. Guideline: Acute phase management with medication. Treatment of major depression. In: Depression in Primary Care, vol. 2. Agency for Health Care Policy and Research Publications, Washington, 1993; 43-70.
28. Okamoto Y. Depressive state. In: Matsushita M, Asai M, Ushijima S et al. (eds) Encyclopedia of Clinical Psychiatry, vol. 17. Nakayama-Shoten, Tokyo, 1998; 42-50.
29. Costa D, Mogos I, Toma T. Efficacy and safety of mianserin in the treatment of depression of woman with cancer. Acta Psychiatrica Scand. 1985; 72: 85-92.
30. Razavi D, Allilaire JF, Smith M et al. The effect of fluoxetine on anxiety and depression symptom in cancer patients. Acta Psychiatrica Scand. 1996; 94: 205-210.
31. Holland JC, Romano SJ, Heiligenstein JH et al. A controlled trial of fluoxetine and desipramine in depressed women with advanced cancer. Psycho-oncology 1998; 7: 291-300.
32. Evans DL, McCartney CF, Haggerty JJ. Treatment of depression in cancer patients is associated with better life adaptation: A pilot study. Psychosom. Med. 1988; 50: 72-76.
33. Beale MD, Kellner CH, Parsons PJ. ECT for the treatment of mood disorders in cancer patients. Convuls. Ther 1997; 13: 222-226.